Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of the ReCor Medical Paradise System in Clinical Hypertension
NCT02649426 · View on ClinicalTrials.gov ↗
Study Summary
RADIANCE-HTN is a randomized, double-blind, sham controlled, 2-cohort study (TRIO and SOLO) designed to demonstrate efficacy and document the safety of the Paradise Renal Denervation System in two distinct populations of hypertensive subjects.
Conditions Studied
Interventions
- DEVICE Sham Procedure
- DEVICE The Paradise® Renal Denervation Ultrasound System
Study Locations (20)
California
- Cedars-Sinai Medical Center — Los Angeles
- Sutter Health Medical Center — Sacramento
Massachusetts
- Massachusetts General Hospital — Boston
- The Brigham and Women's Hospital — Boston
New York
- New York University School of Medicine — New York
- Columbia University / NewYork Presbyterian Hospital — New York
Ohio
- University Hospitals Cleveland Medical Center — Cleveland
- Cleveland Clinic — Cleveland
Alabama
- University of Alabama at Birmingham — Birmingham
Connecticut
- Stamford Hospital — Stamford
Florida
- The Cardiac and Vascular Institute — Gainesville
Georgia
- Emory University Hospital Midtown — Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 282 participants |
| Start Date | 2016-03 |
| Est. Completion | 2025-05 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02649426
The ClinicalTrials.gov registry entry for NCT02649426 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 282 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ReCor Medical, which has 5 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Hypertension appearing as the primary indexed condition, and to 2 interventions — of which Sham Procedure is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT02649426 reports 20 study locations spanning 16 distinct geographic areas — top geographies include California, Massachusetts, New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT02649426 about?
NCT02649426 is a clinical study titled "A Study of the ReCor Medical Paradise System in Clinical Hypertension". RADIANCE-HTN is a randomized, double-blind, sham controlled, 2-cohort study (TRIO and SOLO) designed to demonstrate efficacy and document the safety of the Paradise Renal Denervation System in two distinct populations of hypertensive subjects.
What is the current status of trial NCT02649426?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 282 participants. The study started on 2016-03. Estimated completion is 2025-05.
What conditions does trial NCT02649426 study?
This clinical trial studies the following conditions: Hypertension, Vascular Diseases. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT02649426?
The interventions under investigation include: Sham Procedure (DEVICE), The Paradise® Renal Denervation Ultrasound System (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT02649426?
This trial is sponsored by ReCor Medical, which has 5 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT02649426 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.